Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1626 1691
This examiner grants 71% of resolved cases
Matthew P. Coughlin has overseen 999 resolved cases in Art Unit 1626 of Tech Center 1600. The examiner has an allowance rate of 71.3 percent and a median days to allowance of 888. This volume of 999 cases reflects the examiner's history within the tech center. The 888 median days to allowance provides a timeline for practitioners.
The interview lift for this examiner is 12.4 percent. This lift suggests that for the 999 resolved cases, interviews are a tool to further improve the 71.3 percent allowance rate. Practitioners should aim for resolution to take advantage of the 888 median days to allowance. The 12.4 percent lift and the 71.3 percent allowance rate are the key metrics for Art Unit 1626. These data points offer a view of the examination process for this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18782144 | METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS | Non-Final OA | University of Florida Research Foundation, Inc. |
| 16772768 | SUBSTITUTED AROMATIC AMINES FOR USE IN ORGANIC ELECTROLUMINESCENT DEVICES | Non-Final OA | Merck Patent GmbH |
| 18363004 | ANTIMICROBIAL COMPOSITION COMPRISING A DIOCTYLDIMETHYLAMMONIUM COMPOUND | Non-Final OA | The Procter & Gamble Company |
| 18030935 | Antibacterial And Deodorizing Composition, And Preparation Method Therefor | Non-Final OA | LG Chem, Ltd. |
| 18818163 | BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18015746 | MONOTERPENOID AND PHENYLPROPANOID CARBONATE ESTERS AND METHODS OF THEIR MAKING AND USE AS REPELLENTS | Final Rejection | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. |
| 18375697 | COMPOSITIONS AND METHODS FOR TREATING OCULAR CHEMICAL BURNS | Final Rejection | OHIO STATE INNOVATION FOUNDATION |
| 18828945 | GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS | Non-Final OA | Eli Lilly and Company |
| 18279815 | PYRIMIDINE OR PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS | Final Rejection | King's College London |
| 18039188 | COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS | Final Rejection | IDEMITSU KOSAN CO.,LTD. |
| 18626788 | PROCESS FOR PREPARING SUBSTITUTED CYCLOHEXANE AMINO ACID ESTERS AND SPIROKETAL-SUBSTITUTED CYCLIC KETO-ENOLS | Non-Final OA | Bayer Aktiengesellschaft |
| 18686802 | BETA ADRENERGIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 16882804 | THERAPEUTIC COMPOUNDS | Non-Final OA | Gilead Sciences, Inc. |
| 18123018 | Circularly Recyclable Polymers Featuring Topochemically Elongated Carbon-Carbon Bonds | Non-Final OA | Purdue Research Foundation |
| 18909652 | NLRP3 INFLAMMASOME INHIBITORS | Non-Final OA | Novartis AG |
| 18781034 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18274293 | COMPOSITIONS AND METHODS FOR INHIBITING YAP | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 18599832 | METHOD FOR ATTENUATING NEUROINFLAMMATION, AMYLOIDOPATHY AND TAUOPATHY | Final Rejection | Trustees of Dartmouth College |
| 18259606 | Metal Complexes and Methods for the Same | Non-Final OA | Colgate-Palmolive Company |
| 18555112 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CANCER | Final Rejection | Yale University |
| 17273937 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | Final Rejection | Children`s Medical Center Corporation |
| 18455029 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | Final Rejection | Hoffmann-La Roche Inc. |
| 17976651 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18858952 | SMALL MOLECULE MODULATORS OF HUMAN PREGNANE X RECEPTOR | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 18851346 | 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE | Non-Final OA | GH RESEARCH IRELAND LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy